Literature DB >> 25221656

Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.

Minsoo Han1, Chiman Song2, Nakcheol Jeong3, Hoh-Gyu Hahn2.   

Abstract

For a development of broad spectrum antidepressant 3-aminoazetidine derivatives, two series of compounds were explored by bioisosteric modification of 3-α-oxyazetidine. We synthesized 166 novel 3-aminoazetidine derivatives in series A and B, starting from Boc-protected 3-azetidinone (3) and Boc-protected 3-azetidinal (9) respectively, through parallel syntheses. The inhibitory reuptake activities against serotonin (5-HT), norepinephrine (NE), and dopamine (DA) neurotransmitters were measured by the Neurotransmitter Transporter Uptake Assay Kit using the human embryonic kidney 293 (HEK293) cells stably transfected with the respective three kinds of human transporters (hSERT, hNET, and hDAT). Our study aimed to identify compounds having relative inhibitory activities against hSERT > hNET > hDAT. Lead optimization including microsomal stability, CYP, hERG assay, Ames test, BBB, and PK study resulted in the identification of compound 10dl as a candidate for further studies.

Entities:  

Keywords:  3-aminoazetidines; Depression; bioisosterism; triple reuptake inhibitor

Year:  2014        PMID: 25221656      PMCID: PMC4160755          DOI: 10.1021/ml500187a

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

Review 1.  Use of bupropion in combination with serotonin reuptake inhibitors.

Authors:  Sidney Zisook; A John Rush; Barbara R Haight; Dawn C Clines; Carol B Rockett
Journal:  Biol Psychiatry       Date:  2005-09-13       Impact factor: 13.382

Review 2.  The role of dopamine in the pathophysiology of depression.

Authors:  Boadie W Dunlop; Charles B Nemeroff
Journal:  Arch Gen Psychiatry       Date:  2007-03

3.  Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity.

Authors:  Susanne Jørgensen; Elsebet Østergaard Nielsen; Dan Peters; Tino Dyhring
Journal:  J Neurosci Methods       Date:  2007-12-17       Impact factor: 2.390

4.  6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.

Authors:  Fabrizio Micheli; Paolo Cavanni; Daniele Andreotti; Roberto Arban; Roberto Benedetti; Barbara Bertani; Michela Bettati; Letizia Bettelini; Giorgio Bonanomi; Simone Braggio; Renzo Carletti; Anna Checchia; Mauro Corsi; Elettra Fazzolari; Stefano Fontana; Carla Marchioro; Emilio Merlo-Pich; Michele Negri; Beatrice Oliosi; Emiliangelo Ratti; Kevin D Read; Maja Roscic; Ilaria Sartori; Simone Spada; Giovanna Tedesco; Luca Tarsi; Silvia Terreni; Filippo Visentini; Alessandro Zocchi; Laura Zonzini; Romano Di Fabio
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

5.  hERG channel blockade by externally applied quaternary ammonium derivatives.

Authors:  Kee-Hyun Choi; Chiman Song; Dongyun Shin; Sungnam Park
Journal:  Biochim Biophys Acta       Date:  2011-02-12

Review 6.  Triple uptake inhibitors: therapeutic potential in depression and beyond.

Authors:  Zhengming Chen; Phil Skolnick
Journal:  Expert Opin Investig Drugs       Date:  2007-09       Impact factor: 6.206

Review 7.  The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.

Authors:  Tom Lynch; Amy Price
Journal:  Am Fam Physician       Date:  2007-08-01       Impact factor: 3.292

8.  Novel triple reuptake inhibitors with low risk of CAD associated liabilities: design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.

Authors:  Yuji Ishichi; Eiji Kimura; Eiji Honda; Masato Yoshikawa; Takashi Nakahata; Yasuko Terao; Atsuko Suzuki; Takayuki Kawai; Yuuichi Arakawa; Hiroyuki Ohta; Naoyuki Kanzaki; Hideyuki Nakagawa; Jun Terauchi
Journal:  Bioorg Med Chem       Date:  2013-05-24       Impact factor: 3.641

Review 9.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?

Authors:  Corina Prica; Martine Hascoet; Michel Bourin
Journal:  Behav Brain Res       Date:  2008-07-04       Impact factor: 3.332

View more
  7 in total

1.  Neuroprotective Effect of 3-(Naphthalen-2-Yl(Propoxy)Methyl)Azetidine Hydrochloride on Brain Ischaemia/Reperfusion Injury.

Authors:  Eun-A Kim; Jung-Min Na; Jiae Kim; Soo Young Choi; Jee-Yin Ahn; Sung-Woo Cho
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-28       Impact factor: 4.147

2.  A Stereoselective [3+1] Ring Expansion for the Synthesis of Highly Substituted Methylene Azetidines.

Authors:  Steven C Schmid; Ilia A Guzei; Jennifer M Schomaker
Journal:  Angew Chem Int Ed Engl       Date:  2017-09-01       Impact factor: 15.336

3.  Azetidine synthesis enabled by photo-induced copper catalysis via [3+1] radical cascade cyclization.

Authors:  Jianye Li; Lu Yu; Yun Peng; Bin Chen; Rui Guo; Xiaodong Ma; Xiao-Song Xue; Yunkui Liu; Guozhu Zhang
Journal:  Innovation (Camb)       Date:  2022-04-18

4.  Organic chemistry. Strain-release amination.

Authors:  Ryan Gianatassio; Justin M Lopchuk; Jie Wang; Chung-Mao Pan; Lara R Malins; Liher Prieto; Thomas A Brandt; Michael R Collins; Gary M Gallego; Neal W Sach; Jillian E Spangler; Huichin Zhu; Jinjiang Zhu; Phil S Baran
Journal:  Science       Date:  2016-01-15       Impact factor: 47.728

5.  Anti-inflammatory and anti-oxidative effects of 3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride on β-amyloid-induced microglial activation.

Authors:  Seung-Ju Yang; Jiae Kim; Sang Eun Lee; Jee-Yin Ahn; Soo Young Choi; Sung-Woo Cho
Journal:  BMB Rep       Date:  2017-12       Impact factor: 4.778

6.  Strain-Release Heteroatom Functionalization: Development, Scope, and Stereospecificity.

Authors:  Justin M Lopchuk; Kasper Fjelbye; Yu Kawamata; Lara R Malins; Chung-Mao Pan; Ryan Gianatassio; Jie Wang; Liher Prieto; James Bradow; Thomas A Brandt; Michael R Collins; Jeff Elleraas; Jason Ewanicki; William Farrell; Olugbeminiyi O Fadeyi; Gary M Gallego; James J Mousseau; Robert Oliver; Neal W Sach; Jason K Smith; Jillian E Spangler; Huichin Zhu; Jinjiang Zhu; Phil S Baran
Journal:  J Am Chem Soc       Date:  2017-02-20       Impact factor: 15.419

7.  Protective effect of 3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride on hypoxia-induced toxicity by suppressing microglial activation in BV-2 cells.

Authors:  Jiae Kim; Su-Min Kim; Jung-Min Na; Hoh-Gyu Hahn; Sung-Woo Cho; Seung-Ju Yang
Journal:  BMB Rep       Date:  2016-12       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.